Metformin glycinate

二甲双胍甘氨酸

Report date: 2026/03/19 20:00:18

Base Information

Drug NameMetformin glycinate
Drug Alias Name甘氨二甲双胍glicinato de metforminaglycinate de metforminemetformini glycinasDMMET-01
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionInsulin sensitizersProtein kinase AMP-activated non-catalytic subunit beta 1 activators
TargetsProtein kinase AMP-activated non-catalytic subunit beta 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Metabolic SyndromePrediabetic State +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMexicoEgypt +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesSilanes
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesLaboratorios Silanes Sa De CvNational Hepatology & Tropical Medicine Research Institute
Active IndicationsPrediabetic State
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)Metabolic SyndromeDiabetes Mellitus, Type 2 +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBank